0
The Cutting Edge |

Linear Porokeratosis:  Excellent Response to Photodynamic Therapy FREE

Xavier García-Navarro, MD; Joan Ramon Garcés, MD; Eulàlia Baselga, MD; Agustín Alomar, MD
[+] Author Affiliations

Section Editor: George J. Hruza, MD

Assistant Section Editor: Michael P. Heffernan, MD
Assistant Section Editor: Christie Ammirati, MD

More Author Information
Arch Dermatol. 2009;145(5):526-527. doi:10.1001/archdermatol.2009.45.
Text Size: A A A
Published online

Linear porokeratosis is a skin condition that usually shows a poor response to different modalities of treatment. We describe a patient successfully treated with 2 sessions of photodynamic therapy (PDT).

A 13-year-old boy presented with a 4-year history of reddish-brown hyperkeratotic papules and plaques on the back of his lower leg. The lesions were arranged in a linear pattern and had a raised peripheral ridge and atrophic center (Figure 1). There was no nail dystrophy or other associated abnormalities. His mother had disseminated superficial actinic porokeratosis (DSAP) in the lower extremities. The patient's skin lesions were asymptomatic but cosmetically distressful. Findings from a histopathologic examination showed epidermal hyperplasia with a vertical column of tightly packed parakeratotic cells, the cornoid lamella. These findings were consistent with linear porokeratosis. No response was observed after 1 year of treatment with calcipotriol ointment.

Place holder to copy figure label and caption
Figure 1.

Reddish-brown hyperkeratotic papules and plaques linearly arranged on the back of the right lower leg before treatment.

Graphic Jump Location

There is no known cure for linear porokeratosis, and treatment generally produces disappointing results. However, multiple topical therapies, such as keratolytics, corticosteroids, retinoids, fluorouracil cream, and imiquimod or calcipotriol cream, have been used with variable results.14 Oral acitretin has proven effective in widespread disease, but recurrence following discontinuation is common.5 Other modalities, such as Q-switched ruby laser,6 fractional photothermolisis,7 cryotherapy, carbon dioxide laser ablation, curettage, or dermabrasion,2,5 can be useful in localized lesions but are not feasible for larger lesions owing to the risk of scarring.

After removing the superficial scales with a carbon steel surgical blade, methyl aminolevulinate hydrochloride cream in a 160 mg/g concentration (Metvix; Penn Pharmaceuticals Services, Gwent, South Wales) was applied under occlusion in the medial part of the lesion for 3 hours. Subsequent illumination with red light (light dose of 37 J/cm2) (Aktilite; Photocure ASA, Oslo, Norway) was performed for 9 minutes (Figure 2). Irradiation was well tolerated, and anesthesia was not necessary because the patient noticed only a mild burning sensation. A second session was performed 1 month later. The cosmetic and clinical response was excellent, and the patient was highly satisfied. No recurrence was observed after 11 months (Figure 3), and we are presently treating the remaining lesion.

Place holder to copy figure label and caption
Figure 2.

Erythema and inflammation within the lesions after the first session of photodynamic therapy and methyl aminolevulinate hydrochloride cream.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Clinical aspect of the treated zone 11 months after the second session of photodynamic therapy and methyl aminolevulinate hydrochloride cream.

Graphic Jump Location

Porokeratosis is a group of genetic disorders characterized by clonal proliferation of keratinocytes. Five variants have been identified to date. These include porokeratosis of Mibelli, DSAP, punctate porokeratosis, porokeratosis palmaris et plantaris disseminata, and linear porokeratosis.1

Linear porokeratosis is a rare clinical variant that usually arises in childhood.3 It commonly appears on the extremities as unilateral, linear hyperkeratotic papules and annular plaques. Lesions may coalesce into larger plaques with central atrophy and a raised border along the lines of Blaschko.1,2,4 Nail dystrophy has also been associated with this disorder.4 Linear porokeratosis seems to have an increased risk of transformation into squamous cell carcinoma or basal cell carcinoma and may be exacerbated by immunosuppression, UV light, or irradiation.2,3,5,8 Differential diagnosis includes linear verrucous epidermal nevus, lichen striatus, incontinentia pigmenti, linear lichen planus, linear Darier disease, and warts.9

Photodynamic therapy uses light to activate a photosensitizer in diseased tissue, leading to the formation of cytotoxic reactive oxygen species and selective cell damage.10 At present, it is primarily used to treat actinic keratosis and superficial nonmelanoma cancers.11 We found only 2 reports about treatment of DSAP with PDT.2,3 Both were in adults, and results were contradictory. In the report by Nayeemuddin et al,3 no response was observed in 3 patients with clinical DSAP after treatment with PDT and 5-aminolevulinic acid. Cavicchini and Tourlaki,2 however, obtained an excellent clinical and cosmetic outcome in a patient with DSAP treated with PDT and methyl aminolevulinate cream. These different results may be related to the higher lipophilicity profile of methyl aminolevulinate, a drug that may perhaps penetrate hyperkeratotic lesions of porokeratosis more easily than 5-aminolevulinic acid hydrochloride.2

Treatment with PDT and methyl aminolevulinate cream was administered to our patient because this modality is routinely used for other indications in our setting and because of the efficacy reported by Cavicchini and Tourlaki2 in another type of porokeratosis.

To our knowledge, this is the first report of linear porokeratosis successfully treated with PDT. In our opinion, PDT together with methyl aminolevulinate cream could be an effective and safe alternative to conventional treatments for this disorder. However, controlled studies with a greater number of patients and long-term follow-up are needed to evaluate its real effectiveness. In our patient, no lesion recurrence was observed 11 months after treatment. Further follow-up is needed to determine whether additional sessions are needed to maintain the clinical response.

Correspondence: Xavier García-Navarro, MD, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Sant Antoni M. Claret 167, 08025 Barcelona, Spain (xgarcian@gmail.com).

Accepted for Publication: June 5, 2008.

Author Contributions: Dr García-Navarro had full access to all data in the study and takes responsibility for its integrity and the accuracy of the data analysis. Study concept and design: García-Navarro, Garcés, Baselga, and Alomar. Acquisition of data: García-Navarro. Analysis and interpretation of data: García-Navarro. Drafting of the manuscript: García-Navarro and Baselga. Critical revision of the manuscript for important intellectual content: Garcés and Alomar. Administrative, technical, and material support: García-Navarro. Study supervision: Garcés and Alomar.

Financial Disclosure: None reported.

Ruiz  Villaverde RAlonso  Corral MJSánchez  Cano DPacheco  Sánchez-Lafuente FJ Linear porokeratosis of Mibelli [in Spanish]. An Pediatr (Barc) 2005;63 (4) 376- 377
PubMed
Cavicchini  STourlaki  A Successful treatment of disseminated superficial actinic porokeratosis with methyl aminolevulinate-photodynamic therapy. J Dermatolog Treat 2006;17 (3) 190- 191
PubMed
Nayeemuddin  FAWong  MYell  JRhodes  LE Topical photodynamic therapy in disseminated superficial actinic porokeratosis. Clin Exp Dermatol 2002;27 (8) 703- 706
PubMed
Kim  C Linear porokeratosis. Dermatol Online J 2005;11 (4) 22
PubMed
León-Mateos  ALópez-Escobar  MGómez  S  et al.  Linear porokeratosis. Med Cutan Ibero Lat Am 2003;31 (5) 311- 313
Suárez-Amor  OPereiro-Ferreirós  MGinarte  MPeteiro  CToribio  J Coexistence of linear porokeratosis and disseminated superficial actinic porokeratosis: a type 2 segmental manifestation. Acta Derm Venereol 2007;87 (4) 363- 364
PubMed
Piñeyro  MIMacedo  NAVercelli  J Linear porokeratosis. Med Cutan Ibero Lat Am 2006;34 (6) 303- 305
Itoh  MNakagawa  H Successful treatment of disseminated superficial actinic porokeratosis with Q-switched ruby laser. J Dermatol 2007;34 (12) 816- 820
PubMed
Chrastil  BGlaich  ASGoldberg  LHFriedman  PM Fractional photothermolysis: a novel treatment for disseminated superficial actinic porokeratosis. Arch Dermatol 2007;143 (11) 1450- 1452
PubMed
Ahn  SJLee  HJChang  SE  et al.  Case of linear porokeratosis: successful treatment with topical 5% imiquimod cream. J Dermatol 2007;34 (2) 146- 147
PubMed
Grover  CGoel  ANanda  SKhurana  NReddy  BS A case of extensive linear porokeratosis with evaluation of topical tretinoin versus 5-flourouracil as treatment modalities. J Dermatol 2005;32 (12) 1000- 1004
PubMed

Figures

Place holder to copy figure label and caption
Figure 1.

Reddish-brown hyperkeratotic papules and plaques linearly arranged on the back of the right lower leg before treatment.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Erythema and inflammation within the lesions after the first session of photodynamic therapy and methyl aminolevulinate hydrochloride cream.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Clinical aspect of the treated zone 11 months after the second session of photodynamic therapy and methyl aminolevulinate hydrochloride cream.

Graphic Jump Location

Tables

References

Ruiz  Villaverde RAlonso  Corral MJSánchez  Cano DPacheco  Sánchez-Lafuente FJ Linear porokeratosis of Mibelli [in Spanish]. An Pediatr (Barc) 2005;63 (4) 376- 377
PubMed
Cavicchini  STourlaki  A Successful treatment of disseminated superficial actinic porokeratosis with methyl aminolevulinate-photodynamic therapy. J Dermatolog Treat 2006;17 (3) 190- 191
PubMed
Nayeemuddin  FAWong  MYell  JRhodes  LE Topical photodynamic therapy in disseminated superficial actinic porokeratosis. Clin Exp Dermatol 2002;27 (8) 703- 706
PubMed
Kim  C Linear porokeratosis. Dermatol Online J 2005;11 (4) 22
PubMed
León-Mateos  ALópez-Escobar  MGómez  S  et al.  Linear porokeratosis. Med Cutan Ibero Lat Am 2003;31 (5) 311- 313
Suárez-Amor  OPereiro-Ferreirós  MGinarte  MPeteiro  CToribio  J Coexistence of linear porokeratosis and disseminated superficial actinic porokeratosis: a type 2 segmental manifestation. Acta Derm Venereol 2007;87 (4) 363- 364
PubMed
Piñeyro  MIMacedo  NAVercelli  J Linear porokeratosis. Med Cutan Ibero Lat Am 2006;34 (6) 303- 305
Itoh  MNakagawa  H Successful treatment of disseminated superficial actinic porokeratosis with Q-switched ruby laser. J Dermatol 2007;34 (12) 816- 820
PubMed
Chrastil  BGlaich  ASGoldberg  LHFriedman  PM Fractional photothermolysis: a novel treatment for disseminated superficial actinic porokeratosis. Arch Dermatol 2007;143 (11) 1450- 1452
PubMed
Ahn  SJLee  HJChang  SE  et al.  Case of linear porokeratosis: successful treatment with topical 5% imiquimod cream. J Dermatol 2007;34 (2) 146- 147
PubMed
Grover  CGoel  ANanda  SKhurana  NReddy  BS A case of extensive linear porokeratosis with evaluation of topical tretinoin versus 5-flourouracil as treatment modalities. J Dermatol 2005;32 (12) 1000- 1004
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles